glp 1 liver function Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide Receptor Agonists in Nonalcoholic Fatty Disease Glucagon-like peptide (GLP)-1 and GLP-2

Diabetes Obes Metab (2018) 20 Suppl 1:6876

Please see our T&Cs for further information

Unlike GLP-1 medications, which are primarily designed for diabetes and weight loss, LDN offers broader therapeutic benefits, including immune system regulation and pain management

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have evolved into multi-organ potential therapeutics due to their pleiotropic effects beyond glycemic control